Active, not recruitingPhase 1NCT04454658
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
Studying Primary myelofibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- ABBV-744(drug)
- Enrollment
- 21 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- University of California, Davis Comprehensive Cancer Center /ID# 221790, Sacramento, California, United States
- Duplicate_Dartmouth-Hitchcock Medical Center - 1 Medical Center Drive /ID# 224623, Lebanon, New Hampshire, United States
- Roswell Park Cancer Institute /ID# 222557, Buffalo, New York, United States
- The Mount Sinai Hospital /ID# 221549, New York, New York, United States
- Weill Cornell Medical College /ID# 227069, New York, New York, United States
- Gabrail Cancer Center Research /ID# 222802, Canton, Ohio, United States
- University of Oklahoma, Stephenson Cancer Center /ID# 224095, Oklahoma City, Oklahoma, United States
- Oregon Health and Science University /ID# 221801, Portland, Oregon, United States
- Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 240004, Dallas, Texas, United States
- VA Puget Sound Health Care System /ID# 224208, Seattle, Washington, United States
- Hospital Universitario Austral /ID# 228909, Pilar, Buenos Aires, Argentina
- Hospital Italiano de Buenos Aires /ID# 226945, Ciudad Autonoma Buenos Aires, Buenos Aires F.D., Argentina
- Townsville University Hospital /ID# 225859, Douglas, Queensland, Australia
- Royal Hobart Hospital /ID# 241677, Hobart, Tasmania, Australia
- Royal Perth Hospital /ID# 241678, Perth, Western Australia, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04454658 on ClinicalTrials.govOther trials for Primary myelofibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07104799Momelotinib During and After HCT in MyelofibrosisMassachusetts General Hospital
- RECRUITINGPHASE3NCT07317700A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT07128381Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT06887803A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK InhibitorsiOnctura
- RECRUITINGPHASE1, PHASE2NCT07281781Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone MarrowUniversity of California, Irvine
- ACTIVE NOT RECRUITINGNCT07342712Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation LevelsFirst Affiliated Hospital of Zhejiang University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06909136A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With MyelofibrosisSuzhou Junjing BioSciences Co., Ltd.
- RECRUITINGPHASE2NCT06770842Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisThe University of Hong Kong